{
    "clinical_study": {
        "@rank": "87250", 
        "acronym": "NEFIMAR", 
        "arm_group": {
            "arm_group_label": "Neurofibromatosis 1", 
            "description": "All patients diagnosed with neurofibromatosis type 1. GROUP 1:ADDITIONAL IMAGING OR SURGERY There will be patients with high-risk neurofibromas (potential malignant). These patients will underwent additional examinations or surgery (outside this study). Follow-up MRI within 2 years (study MRI )\nGROUP 2:\nNo suspicious lesions at MRI. Follow-up within 2 years(Study MRI)."
        }, 
        "brief_summary": {
            "textblock": "Whole body MRI will be performed in patients with neurofibromatosis Type 1\n\n      PURPOSE 1:\n\n      To determine the total tumor load (neurofibroma) and to diagnose plexiform neurofibromas or\n      malignant peripheral nerve sheath tumors. All patients will be scanned two years after the\n      baseline whole body MRI to investigate to investigate the changes of total tumor load.\n\n      PURPOSE 2: added value of diffusion weighted imaging in diagnosis of high-risk neurofibromas\n\n      PURPOSE 3 : to determine the apparent diffusion coefficient of the malignant nerve sheath\n      tumors and neurofibroma.\n\n      PURPOSE 4 : correlation between histopathology of the surgically resected\n      neurofibroma/malignant nerve sheath tumors and MRI findings"
        }, 
        "brief_title": "Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Whole Body Imaging", 
            "Magnetic Resonance Imaging", 
            "Neurofibromatosis 1", 
            "Diffusion Magnetic Resonance Imaging", 
            "Peripheral Nerve Sheath Tumors, Malignant"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neurofibromatoses", 
                "Neurofibromatosis 1", 
                "Osteitis Fibrosa Cystica", 
                "Nerve Sheath Neoplasms", 
                "Neurofibrosarcoma", 
                "Neurilemmoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with neurofibromatosis type 1, between 6 and 50 years old\n\n        Exclusion Criteria:\n\n          -  Patients who are not allowed to be scanned on MRI (contra-indications: pacemaker ed.)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "6 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "All patients with a clinically proven neurofibromatosis type 1 can be included."
            }
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01777451", 
            "org_study_id": "NEFIMAR", 
            "secondary_id": "S52684"
        }, 
        "intervention": {
            "arm_group_label": "Neurofibromatosis 1", 
            "description": "No specific intervention is necessary. If a suspicious lesion is diagnosed on MRI, further investigation will be planned (PET-CT or surgery - biopsy)", 
            "intervention_name": "Additional imaging or surgery", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Whole Body Imaging", 
            "Magnetic Resonance Imaging", 
            "Neurofibromatosis 1", 
            "Diffusion Magnetic Resonance Imaging", 
            "Peripheral Nerve Sheath Tumors, Malignant"
        ], 
        "lastchanged_date": "January 23, 2013", 
        "location": {
            "contact": {
                "email": "steven.pans@uzleuven.be", 
                "last_name": "Steven Pans, MD", 
                "phone": "3216340505"
            }, 
            "facility": {
                "address": {
                    "city": "Leuven", 
                    "country": "Belgium"
                }, 
                "name": "University Hospitals Leuven"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_groups": "1", 
        "official_title": "Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis", 
        "overall_contact": {
            "email": "steven.pans@uzleuven.be", 
            "last_name": "Steven Pans, MD", 
            "phone": "3216340505s"
        }, 
        "overall_official": {
            "affiliation": "Universitaire Ziekenhuizen Leuven", 
            "last_name": "Steven Pans, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Estimation of the total tumor load of neurofibromas with whole body MRI (head to knee). Diagnosis of high risk neurofibroma in the chest, abdomen, pelvis, and extremities with T2-weighted sequence and diffusion weighted sequence.", 
            "measure": "Estimation of total tumor load and diagnosis of high-risk neurofibromas", 
            "safety_issue": "No", 
            "time_frame": "1 month"
        }, 
        "reference": [
            {
                "PMID": "18930997", 
                "citation": "Tucker T, Friedman JM, Friedrich RE, Wenzel R, F\u00fcnsterer C, Mautner VF. Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas. J Med Genet. 2009 Feb;46(2):81-5. doi: 10.1136/jmg.2008.061051. Epub 2008 Oct 17."
            }, 
            {
                "PMID": "19244040", 
                "citation": "Cai W, Kassarjian A, Bredella MA, Harris GJ, Yoshida H, Mautner VF, Wenzel R, Plotkin SR. Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images. Radiology. 2009 Mar;250(3):665-73. doi: 10.1148/radiol.2503080700."
            }, 
            {
                "PMID": "19091504", 
                "citation": "Van Meerbeeck SF, Verstraete KL, Janssens S, Mortier G. Whole body MR imaging in neurofibromatosis type 1. Eur J Radiol. 2009 Feb;69(2):236-42. doi: 10.1016/j.ejrad.2008.10.024. Epub 2008 Dec 16."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01777451"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universitaire Ziekenhuizen Leuven", 
            "investigator_full_name": "Steven Pans", 
            "investigator_title": "Medical Doctor Radiologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Some patients with neurofibromatosis have lesions, pre-malignant or malignant neurofibromas. Additional imaging (PET-CT), a biopsy or surgical treatment is necessary in combination with histopathology of the lesion.", 
            "measure": "To diagnose high-risk neurofibroma", 
            "safety_issue": "No", 
            "time_frame": "2 months"
        }, 
        "source": "Universitaire Ziekenhuizen Leuven", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universitaire Ziekenhuizen Leuven", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2010", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2013"
    }
}